Anti-diabetic
- Metformin
Building local pharmaceutical excellence
A medium-scale facility focused on high-demand generic medicines, strengthening the Kingdom's drug security.
USD 15 Million
Total project investment
50-70 Million
Units per year
2,000-3,000 m2
Planned facility area
24-30 Months
Estimated implementation
USD 7+ Billion
Saudi pharmaceutical market size
7-9%
Estimated market growth
80%+
Import dependency in the Kingdom
25-30%
Annual ROI after year two
Product portfolio
Four therapeutic categories at launch
Cardiovascular
- Atorvastatin
- Amlodipine
Gastrointestinal
- Omeprazole
Analgesics and anti-inflammatories
- Paracetamol
- Ibuprofen
Fifteen million in, and what it returns
USD 12-18M
Annual revenue potential
35-40%
Gross profit margin
20-25%
EBITDA margin
5-7 Years
Payback period
Full breakdown
- Land and building
- USD 4.5M
- Machinery and equipment
- USD 6.0M
- Utilities and installation
- USD 1.0M
- Raw material inventory
- USD 2.0M
- SFDA registration and consultancy
- USD 0.5M
- Initial marketing and salaries
- USD 1.0M
- Total capital expenditure
- USD 11.5M
- Working capital and pre-operational
- USD 3.5M
- Annual EBITDA potential
- USD 3-5M
The incentive environment, by benefit type
Tax
- Corporate tax
- 0% up to 20 years
- Effect
- Higher long-term returns
Financing
- Potential SIDF financing
- 75% of project cost
- Effect
- Reduced equity requirement
Procurement
- Government price preference
- 10-15%
- Effect
- Advantage in public tenders
Duty
- Exemption value
- USD 300K-500K
- Applies to
- Imported machinery and raw materials
Twenty-four to thirty months to commercial launch
6 months
Planning and approvals
Manufacturing licence and product registration with SFDA.
12 months
Design and construction
Facility build to GMP specification.
6 months
Procurement and installation
Machinery delivery, installation and qualification.
6 to 12 months
Regulatory and commissioning
GMP compliance, pre-approval inspection and validation studies.
Operations begin
Commercial launch
First commercial batches released to market.
A healthier future for Saudi Arabia
- Healthcare localisation under Vision 2030
- Import dependency reduction across essential medicines
- Skilled job creation and economic growth
- Stronger national drug security